Thiakis

Thiakis

Advent contact Raj Parekh

Company CEO John Burt


Obesity therapy

Acquired by Pfizer

Thiakis was founded in 2004 in London to develop novel medicines for the treatment of obesity and co-morbidities based on original research of Professor Steve Bloom and his colleagues at Imperial College London. Thiakis' lead product candidate, TKS1225, is being studied for the treatment of medical obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin.

Wyeth Pharmaceuticals acquires Thiakis in a transaction worth up to £100m


Back